Opus Genetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRD research report →
About the company
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders.
- CEO
- George Magrath
- IPO
- 2015
- Employees
- 18
- HQ
- Durham, MI, US
Price Chart
- Market Cap
- $349.25M
- P/E
- -3.23
- P/S
- 29.15
- P/B
- -80.19
- EV/EBITDA
- -3.01
- Div Yield
- 0.00%
- Gross Margin
- 49.64%
- Op Margin
- -359.13%
- Net Margin
- -892.36%
- ROE
- 6068.79%
- ROIC
- -74.91%
- Revenue
- $14.20M · 29.15%
- Net Income
- $-49,591,000 · 13.80%
- EPS
- $-0.80 · 62.79%
- Op Income
- $-38,599,000
- FCF YoY
- -37.84%
- 52W High
- $5.81
- 52W Low
- $0.98
- 50D MA
- $4.47
- 200D MA
- $3.28
- Beta
- 0.55
- Avg Volume
- 979.39K
Get TickerSpark's AI analysis on IRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Foundation Fighting Blindness Retinal Degeneration Fund | sell | 1,700,000 |
| Apr 23, 26 | YERXA BENJAMIN R | sell | 7,470 |
| Apr 23, 26 | SCHACHLE JOSEPH K | sell | 4,697 |
| Apr 23, 26 | Zaremba Rabourn Amy | sell | 1,641 |
| Apr 23, 26 | Magrath George | sell | 9,511 |
| Apr 23, 26 | Jayagopal Ashwath | sell | 7,542 |
| Apr 23, 26 | Gagnon Robert E. | sell | 7,842 |
| Apr 20, 26 | Rodgers Richard J | other | 24,367 |
| Apr 20, 26 | MANUSO JAMES S J | other | 24,367 |
| Apr 20, 26 | Graves Adrienne L | other | 24,367 |
Our IRD coverage
Recent articles, reports, and earnings notes.
No research on IRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRD report →Similar companies
Peers in the same neighborhood.